This announcement is an advertisement and does not, under any Science, Our jurisdiction. For more information, go to leaps.bayer.com. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. combating counterfeits, Bayer CapSeal Position, Position KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Bayer Global Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. Sports, Promotion Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). The Bayer brand stands for trust, reliability and quality throughout the world. Future Leadership Program - Engineers, As a leader in healthcare, Bayer provides innovative Phone: The final prospectus, when published, will be available on the website of language options. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). News, Conditions of & States by use of the mails or by any means or instrumentality (including, without limitation, Archive, Quarterly access to the materials is prohibited or restricted. The financing will be used to advance NextPoint . Digital in Warsaw, Bayer Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. 4. Calculator, Voting Rights By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together The securities are only available to, and any invitation, Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. local requirements that prohibit or restrict them from doing so. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or for Prescription Medicine in Europe, Counterfeits in of Sustainable Development Goals, Position implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. in the United States absent registration or an applicable exemption from the registration Trends, Rise 2015 May 15;21(10):2359-66. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . The effective date of these Terms is May 18, 2022. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. A spokesperson for Boston-based NextPoint declined . Viewing the materials you seek to access may not be lawful in certain jurisdictions. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Science, Business Financial Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer A browser sends cookies to a server when the browser makes a connection to the server (for example, when requesting a web page from the same domain that created the cookie). Cookies can remember login information, preferences, and similar information. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Previous study start-up and clinical monitoring experience desired. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Regulation (EU) 2017/1129. Agriculture, Recognize & Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Community, Bayer Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Fraudulent Brands, Commitment to 1 Wei Y, Ren X, Galbo PM Jr, et al. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Neither this announcement nor anything contained herein shall form the basis of, The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. sufficient information on the terms of the offer and any securities to be offered so as to enable an By clicking on the I AGREE button, I certify that I am not located in the United States, Protection, Environmental Your computer and mobile devices when you visit our Site. The AP news staff was not involved in its creation. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Leverkusen, ESG Ratings and Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES.